{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135267","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.106296+00:00","generated_at":"2026-06-02T06:40:37.864492+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcellx Q1 net loss narrows to $7.2M; collaboration revenue rises to $39.3M","bullets":["Cash, cash equivalents, and marketable securities of $691.0M as of March 31, 2024; funds operations into 2027.","Collaboration revenue $39.3M, up $21.4M YoY, driven by Kite Pharma agreement amendments.","Net loss of $7.2M vs $27.3M in Q1 2023, an improvement of $20.1M.","R&D expenses $32.3M (down $0.6M YoY); G&A expenses $22.7M (up $7.3M YoY) on higher personnel costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135267","json":"https://secwatch.observer/filing/0001193125-24-135267.json","markdown":"https://secwatch.observer/filing/0001193125-24-135267.md","text":"https://secwatch.observer/filing/0001193125-24-135267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524135267/0001193125-24-135267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524135267/d837604d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:40:37.864492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c05c7d4738a6bc176407a29472d342d1df85742","claim":"Arcellx, Inc. reported for the first quarter ended March 31, 2024 results: revenue $39.3 million, net income Net loss was $7.2 million.","evidence_excerpt":"million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. Collaboration revenue: Collaboration revenue were $39.3 million and $17.9 million for the quarters ended March 31, 2024 and 2023, respectively, an increase of $21.4 million. This increase was primarily driven by changes in estimated","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000119312524135267/0001193125-24-135267-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$39.3 million"},{"label":"Net income","value":"Net loss was $7.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}